@article{5ac6635e2492447a87421b6a80931c3d,
title = "Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen–Targeting Small Interfering RNA",
keywords = "angiotensinogen, hypertension therapy, reversibility, siRNA, zilebesiran",
author = "Priyanga Ranasinghe and Addison, {Melisande L.} and Webb, {David J.}",
note = "Funding Information: D.J.W. has received nonpersonal support for research and consultancy from AbbVie, Actelion, AstraZeneca, Idorsia, Johnson & Johnson, and Novartis. D.J.W. has received funding for research in hypertension from the British Heart Foundation. University/British Heart Foundation Centre for Cardiovascular Science received funding from Alnylam Pharmaceuticals for phase I trials with zilebesiran. The remaining authors have no disclosures to report.",
year = "2022",
month = oct,
day = "10",
doi = "10.1161/JAHA.122.027694",
language = "English",
volume = "11",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley Open Access",
number = "20",
}